Anti-BCMA/GPRC5D Bispecific CAR T Cells for Relapsed or Refractory Multiple Myeloma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Anti-BCMA/GPRC5D bispecific CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, single-centre, phase 1 trial
Lancet Haematol 2024 Jul 23;[EPub Ahead of Print], D Zhou, Q Sun, J Xia, W Gu, J Qian, W Zhuang, Z Yan, H Cheng, W Chen, F Zhu, K Qi, D Li, W Sang, L Zhu, S Ma, H Li, H Zhang, T Qiu, D Yan, Y Zhang, S Peng, AH Chang, K Xu, Z LiFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.